mercredi 15 avril 2020

Onco Actu du 15 avril 2020


4.11 DÉP., DIAG. & PRONO. - OVAIRE



Multi-Omic Analysis Highlights Molecular Differences Among Ovarian Cancer Subgroups [Genome Web]











5.1 TRAITEMENTS - PRÉ-CLINIQUE



Experimental drug offers hope for preventing cancer relapse [Francis Crick Institute]











5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE



Yale test of immunotherapy drug for advanced lung cancer shows promise [Yale]











Moffitt Researchers Identify Molecular Pathway That Controls Immunosuppression in Tumors [Moffitt Cancer Center]











Turning cold tumors hot: Drug delivery system makes immunotherapy more effective [University of Chicago]











5.12.13 IMMUNOTHÉRAPIES - BIOMARQUEURS



Merck Bid for Second Pan-Cancer Keytruda Indication Would Raise Tumor Mutation Burden to CDx Status [Genome Web]











5.2 PHARMA



Merck Announces US Launch of ONTRUZANT® (trastuzumab-dttb), a Biosimilar of Herceptin® (trastuzumab) [Merck]











5.2.1 PHARMA - PARTENARIATS



Novartis, TScan unite on TCR treatments for solid tumors [Fierce Biotech]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



FDA Approves Encorafenib in Combination with Cetuximab for mCRC with a BRAF V600E Mutation [ESMO]











Selumetinib Approved by FDA to Treat Children with NF1 [NCI]










6.15 LUTTE CONTRE LES CANCERS - COVID-19



Taking care of older patients with cancer in the context of COVID-19 pandemic [The Lancet Oncology]










Things should never be the same again in the screening world [BMJ]